<span item_type="fundamental" item_id="f69cb35159bdd18395778a33314dffea" counter_id="ST/US/CERS" env="prod"></span><span item_type="announcement" item_id="546192334704803969" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 60.13 M, beating the estimate of USD 51.8 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.03.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -5.639 M, missing the estimate of USD -3.379 M.</p><p></p><h3>Segment Revenue</h3><h4>Product Revenue</h4><ul><li><strong>Three Months Ended June 30, 2025</strong>: $52.445 million</li><li><strong>Three Months Ended June 30, 2024</strong>: $45.079 million</li><li><strong>Change</strong>: $7.366 million (16%)</li><li><strong>Six Months Ended June 30, 2025</strong>: $95.684 million</li><li><strong>Six Months Ended June 30, 2024</strong>: $83.444 million</li><li><strong>Change</strong>: $12.240 million (15%)</li></ul><h4>Government Contract Revenue</h4><ul><li><strong>Three Months Ended June 30, 2025</strong>: $7.684 million</li><li><strong>Three Months Ended June 30, 2024</strong>: $5.440 million</li><li><strong>Change</strong>: $2.244 million (41%)</li><li><strong>Six Months Ended June 30, 2025</strong>: $13.298 million</li><li><strong>Six Months Ended June 30, 2024</strong>: $10.470 million</li><li><strong>Change</strong>: $2.828 million (27%)</li></ul><h3>Operational Metrics</h3><h4>Cost of Product Revenue</h4><ul><li><strong>Three Months Ended June 30, 2025</strong>: $23.470 million</li><li><strong>Three Months Ended June 30, 2024</strong>: $20.413 million</li><li><strong>Change</strong>: $3.057 million (15%)</li><li><strong>Six Months Ended June 30, 2025</strong>: $41.285 million</li><li><strong>Six Months Ended June 30, 2024</strong>: $37.506 million</li><li><strong>Change</strong>: $3.779 million (10%)</li></ul><h4>Gross Margin on Product Sales</h4><ul><li><strong>Three Months Ended June 30, 2025</strong>: 55%</li><li><strong>Three Months Ended June 30, 2024</strong>: 55%</li><li><strong>Six Months Ended June 30, 2025</strong>: 57%</li><li><strong>Six Months Ended June 30, 2024</strong>: 55%</li></ul><h4>Research and Development Expenses</h4><ul><li><strong>Three Months Ended June 30, 2025</strong>: $18.900 million</li><li><strong>Three Months Ended June 30, 2024</strong>: $14.969 million</li><li><strong>Change</strong>: $3.931 million (26%)</li><li><strong>Six Months Ended June 30, 2025</strong>: $35.505 million</li><li><strong>Six Months Ended June 30, 2024</strong>: $29.451 million</li><li><strong>Change</strong>: $6.054 million (21%)</li></ul><h4>Selling, General and Administrative Expenses</h4><ul><li><strong>Three Months Ended June 30, 2025</strong>: $21.182 million</li><li><strong>Three Months Ended June 30, 2024</strong>: $18.973 million</li><li><strong>Change</strong>: $2.209 million (12%)</li><li><strong>Six Months Ended June 30, 2025</strong>: $41.468 million</li><li><strong>Six Months Ended June 30, 2024</strong>: $38.772 million</li><li><strong>Change</strong>: $2.696 million (7%)</li></ul><h4>Non-Operating Expense, Net</h4><ul><li><strong>Foreign Exchange (Loss) Gain</strong><ul><li><strong>Three Months Ended June 30, 2025</strong>: - $911 thousand</li><li><strong>Three Months Ended June 30, 2024</strong>: - $77 thousand</li><li><strong>Change</strong>: - $834 thousand (1083%)</li><li><strong>Six Months Ended June 30, 2025</strong>: - $1.198 million</li><li><strong>Six Months Ended June 30, 2024</strong>: $68 thousand</li><li><strong>Change</strong>: - $1.266 million (1862%)</li></ul></li><li><strong>Interest Expense</strong><ul><li><strong>Three Months Ended June 30, 2025</strong>: - $2.150 million</li><li><strong>Three Months Ended June 30, 2024</strong>: - $2.330 million</li><li><strong>Change</strong>: $180 thousand (8%)</li><li><strong>Six Months Ended June 30, 2025</strong>: - $4.260 million</li><li><strong>Six Months Ended June 30, 2024</strong>: - $4.564 million</li><li><strong>Change</strong>: $304 thousand (7%)</li></ul></li><li><strong>Other Income, Net</strong><ul><li><strong>Three Months Ended June 30, 2025</strong>: $845 thousand</li><li><strong>Three Months Ended June 30, 2024</strong>: $412 thousand</li><li><strong>Change</strong>: $433 thousand (105%)</li><li><strong>Six Months Ended June 30, 2025</strong>: $1.451 million</li><li><strong>Six Months Ended June 30, 2024</strong>: $864 thousand</li><li><strong>Change</strong>: $587 thousand (68%)</li></ul></li><li><strong>Total Non-Operating Expense, Net</strong><ul><li><strong>Three Months Ended June 30, 2025</strong>: - $2.216 million</li><li><strong>Three Months Ended June 30, 2024</strong>: - $1.995 million</li><li><strong>Change</strong>: - $221 thousand (11%)</li><li><strong>Six Months Ended June 30, 2025</strong>: - $4.007 million</li><li><strong>Six Months Ended June 30, 2024</strong>: - $3.632 million</li><li><strong>Change</strong>: - $375 thousand (10%)</li></ul></li></ul><h4>Provision for Income Taxes</h4><ul><li><strong>Three Months Ended June 30, 2025</strong>: $76 thousand</li><li><strong>Three Months Ended June 30, 2024</strong>: - $56 thousand</li><li><strong>Change</strong>: $132 thousand (236%)</li><li><strong>Six Months Ended June 30, 2025</strong>: $150 thousand</li><li><strong>Six Months Ended June 30, 2024</strong>: $18 thousand</li><li><strong>Change</strong>: $132 thousand (733%)</li></ul><h3>Cash Flow</h3><h4>Net Cash (Used in) Provided by Operating Activities</h4><ul><li><strong>Six Months Ended June 30, 2025</strong>: - $3.290 million</li><li><strong>Six Months Ended June 30, 2024</strong>: $2.360 million</li></ul><h4>Net Cash Used in Investing Activities</h4><ul><li><strong>Six Months Ended June 30, 2025</strong>: - $2.278 million</li><li><strong>Six Months Ended June 30, 2024</strong>: - $5.661 million</li></ul><h4>Net Cash Provided by Financing Activities</h4><ul><li><strong>Six Months Ended June 30, 2025</strong>: $942 thousand</li><li><strong>Six Months Ended June 30, 2024</strong>: $4.158 million</li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li><strong>Product Revenue</strong>: Expected to increase in future periods driven by growth in global platelet business due to increased market acceptance and adoption in geographies where commercialization efforts are underway.</li><li><strong>Government Contract Revenue</strong>: Anticipated to increase through fiscal year 2026 as multiple contracts are active and activities supporting those contracts ramp up.</li></ul><h4>Non-Core Business</h4><ul><li><strong>IFC Sales</strong>: Limited until sufficient INTERCEPT Blood System for Cryoprecipitation kits are sold to blood center affiliate organizations or the number of manufacturing partners producing IFC is expanded.</li></ul><h4>Priority</h4><ul><li><strong>Regulatory Approvals</strong>: Efforts to obtain regulatory approval for new LED-based illuminator and additional configurations of the platelet system in the U.S. and other geographies.</li><li><strong>Manufacturing Capacity</strong>: Investments in capital equipment, capacity expansion, and cost reduction projects with suppliers to meet growing demand for products.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1020214/000095017025103179/cers-20250630.htm"></span></li></ul>

Cerus | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 60.13 M